Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
about
2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces rapid actin polymerization in HL-60 cells differentiated into macrophage-like cellsN-arachidonyl maleimide potentiates the pharmacological and biochemical effects of the endocannabinoid 2-arachidonylglycerol through inhibition of monoacylglycerol lipaseReduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptorDespite substantial degradation, 2-arachidonoylglycerol is a potent full efficacy agonist mediating CB(1) receptor-dependent G-protein activation in rat cerebellar membranesPathophysiological role of host microbiota in the development of obesityCannabinoid-based drugs targeting CB1 and TRPV1, the sympathetic nervous system, and arthritisChemical probes of endocannabinoid metabolismEndocannabinoid signaling, glucocorticoid-mediated negative feedback, and regulation of the hypothalamic-pituitary-adrenal axisModulation of the endocannabinoid system: vulnerability factor and new treatment target for stimulant addiction2-arachidonoylglycerol induces the migration of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanismThe endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cellsPharmacogenetic trial of a cannabinoid agonist shows reduced fasting colonic motility in patients with nonconstipated irritable bowel syndromeChronic monoacylglycerol lipase blockade causes functional antagonism of the endocannabinoid system.Developmental regulation of fear learning and anxiety behavior by endocannabinoids.Endogenous cannabinoid signaling is required for voluntary exercise-induced enhancement of progenitor cell proliferation in the hippocampus.The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors.Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout miceEnhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modalityA missense mutation in human fatty acid amide hydrolase associated with problem drug use.Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental modelsInvolvement of the endocannabinoid system in the neurobehavioural effects of stress and glucocorticoidsFast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling.Identification and recombinant expression of anandamide hydrolyzing enzyme from Dictyostelium discoideum.Endocannabinoid 2-Arachidonoylglycerol Self-Administration by Sprague-Dawley Rats and Stimulation of in vivo Dopamine Transmission in the Nucleus Accumbens Shell.Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice.JZL184 is anti-hyperalgesic in a murine model of cisplatin-induced peripheral neuropathy.Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment.Endocannabinoid modulation by FAAH and monoacylglycerol lipase within the analgesic circuitry of the periaqueductal greyEndocannabinoid signaling in midbrain dopamine neurons: more than physiology?Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress.Cellular accumulation of anandamide: consensus and controversy.Cannabinoid receptor systems: therapeutic targets for tumour intervention.Changes in N-acylethanolamine Pathway Related Metabolites in a Rat Model of Cerebral Ischemia/Reperfusion.Multiple Forms of Endocannabinoid and Endovanilloid Signaling Regulate the Tonic Control of GABA Release.Refined homology model of monoacylglycerol lipase: toward a selective inhibitor.Cannabinoid type-1 receptor reduces pain and neurotoxicity produced by chemotherapy.Endocannabinoids and their implications for epilepsy.Inhibition of 2-arachidonoylglycerol catabolism modulates vasoconstriction of rat middle cerebral artery by the thromboxane mimetic, U-46619.Lipid profiling reveals arachidonate deficiency in RAW264.7 cells: Structural and functional implications.Role of cannabinoids and endocannabinoids in cerebral ischemia.
P2860
Q24528166-66F4B444-0ACA-4DF6-88AC-E59BC511D56EQ24569817-815B3516-BD5E-4BC4-8ECD-D17578F8E9CDQ24672600-22FE109F-F7A9-4EBA-81C0-EEB1DDE4A83CQ24673517-E4BD75F4-F83D-492D-BF0E-96EED58E3FD1Q26750893-3D1A39B0-0B3A-42D9-9B78-61EF61C2F4B5Q26783956-2ED4886E-D608-458F-B40F-F9CB23E3EC15Q26863202-FB2A5F24-1797-461A-9618-F5857ED26F5CQ26991850-14C1D9D5-5352-4B80-86C4-AFBD68FCFDFAQ27014154-1C40E4E2-1F19-4D11-91A9-231F860C443CQ28200894-4C90D52B-207D-485B-A014-706CBA500656Q28236199-FE36F7EC-6744-4E5B-9653-05AFE140E626Q28244460-8C27EAF3-B45C-4CFA-9AB7-0E55D447AACDQ28590486-8BB43D40-18AC-4940-B137-7FE5D7BF0D8EQ30366747-F281DB63-40F4-42C6-AB8D-0C650C6A0120Q33759419-FD95D29D-2B9B-46D2-98E7-E031D615072FQ33940288-4B16254C-449B-48CA-B9CD-3534521C40ABQ33943990-098D8A26-7DF6-4FB6-9DF3-B98078AB9F9DQ34018061-D021CC6D-A28E-4CBB-B680-323DF591ABE2Q34032872-434AE1F7-B5CB-416A-9E89-3AC3CE13ABA8Q34098209-58CA495E-468A-414C-853D-BC2A3B7376ABQ34153898-7744170C-B42C-46AF-99E7-B89395CF3582Q34157484-BD140A1D-0B79-4326-81B8-8BB0EB3879E2Q34316389-A5D899C1-15DE-4A79-AEF3-51E06697A204Q34359778-A818417B-E658-4F17-91FA-F14AAABF026CQ34438163-A7C14570-D8C5-4606-9E7A-F1E437514F02Q34715335-CE3AA107-AD0C-43FF-B5A1-A76D41F8A983Q34798544-6C1B87E1-BED8-4207-BD55-7338049E8700Q34953319-E9FDE1FB-63D0-4A99-B734-E30E2E0CEA83Q34967151-11744178-F7DC-4372-9230-0C88D51C259EQ35054642-CD105CF2-8CF0-4364-AFC1-E5E108CD9C97Q35217244-A3CFE0F9-7CCB-490D-A346-305C2392AF7FQ35593944-AF5E3C8C-6EDF-47FA-AA07-1515C9F10310Q35688321-7C8FC601-AC77-4E93-BB47-5C32951CE9DBQ35829479-13950A56-AC48-4B5F-B0FC-22C812B01FF5Q35841379-ECA1AFCD-BC19-47EB-85E9-C8327EC159BCQ36006338-BD6A8CF9-D18C-4D6F-97F5-D97ECB86D822Q36214144-82B1152C-5577-4345-8307-4FC8A8DC6EE7Q36358717-9BCC6734-16EA-43A9-AC1D-0091A258F601Q36744929-F66194F8-9ECB-42E8-951D-B4618216EF7EQ36967863-9A33BCC8-AB48-4D27-B74E-0E22B664CA96
P2860
Biochemistry and pharmacology of the endocannabinoids arachidonylethanolamide and 2-arachidonylglycerol.
description
2000 nî lūn-bûn
@nan
2000 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Biochemistry and pharmacology ...... ide and 2-arachidonylglycerol.
@ast
Biochemistry and pharmacology ...... ide and 2-arachidonylglycerol.
@en
type
label
Biochemistry and pharmacology ...... ide and 2-arachidonylglycerol.
@ast
Biochemistry and pharmacology ...... ide and 2-arachidonylglycerol.
@en
prefLabel
Biochemistry and pharmacology ...... ide and 2-arachidonylglycerol.
@ast
Biochemistry and pharmacology ...... ide and 2-arachidonylglycerol.
@en
P1476
Biochemistry and pharmacology ...... ide and 2-arachidonylglycerol.
@en
P2093
C J Hillard
P356
10.1016/S0090-6980(00)00051-4
P577
2000-04-01T00:00:00Z